Adverse Events of Adjuvant Mitotane Treatment for Adrenocortical Carcinoma.
Endocr Res
; : 1-7, 2024 Sep 15.
Article
en En
| MEDLINE
| ID: mdl-39277812
ABSTRACT
BACKGROUND:
Mitotane is the cornerstone of adjuvant adrenocortical cancer (ACC) treatment. However, its use is burdened with frequent adverse events.METHODS:
A retrospective analysis of adverse events was performed in 26 ACC patients adjuvantly treated with mitotane.RESULTS:
Mitotane toxicity was present in all patients (100%). Two (7.7%) patients developed 1-3 adverse events, 15 (57.7%) experienced 4-6 adverse events and 9 (34.6%) patients had more than 6 adverse events. Two (7.7%) patients discontinued mitotane due to adverse events.CONCLUSION:
Careful monitoring and timely management are essential for ensuring mitotane treatment adherence and maximizing its benefits.
Texto completo:
1
Bases de datos:
MEDLINE
Idioma:
En
Revista:
Endocr Res
Asunto de la revista:
ENDOCRINOLOGIA
Año:
2024
Tipo del documento:
Article
País de afiliación:
Croacia